Roivant Sciences (ROIV) net assets (shareholders' equity)

Net assets · fiscal 2026
$4.53B

Roivant Sciences (ROIV) had net assets of $4.53B at the end of fiscal 2026 (March 31, 2026). That is 3.4% lower than the $4.69B of fiscal 2025. Figures as of 19 Nov 2026, 07:39 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2026
$4.53B
Change on fiscal 2025
−3.4%
Growth, 5 years
+20.3% a year
Highest on record
$5.97Bfiscal 2024
Lowest on record
$1.16Bfiscal 2023
Fiscal years on record
62021–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Roivant Sciences net assets (shareholders' equity), in more detail

Over the five fiscal years to 2026 net assets grew at a compound 20.3% a year. Across the 6 fiscal years on record (2021–2026), the highest was $5.97B in fiscal 2024 and the lowest $1.16B in fiscal 2023.

History · 6 fiscal years

Net assets by fiscal year

Roivant Sciences net assets (shareholders' equity), year by year

Roivant Sciences (ROIV) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2026$4.53B 3.4% down
2025$4.69B 21.5% down
2024$5.97B 415.5% up
2023$1.16B 30.1% down
2022$1.66B 7.8% down
2021$1.80B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Roivant Sciences and comparable companies
CompanyNet assetsFiscal year
Labcorp Holdings LH$8.62B2025
DexCom DXCM$2.75B2025
Koninklijke Philips PHG€10.96B2025
Roivant Sciences ROIV$4.53B2026
West Pharmaceutical Services WST$3.18B2025
Quest Diagnostics DGX$7.17B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ROIV

Roivant Sciences, figure by figure

Roivant Sciences (ROIV) overview: price, valuation and scorecardAll health care companies by market value

Roivant Sciences net assets (shareholders' equity): questions and answers

What are Roivant Sciences's net assets?

Roivant Sciences (ROIV) had net assets of $4.53B at the end of fiscal 2026 (March 31, 2026). That is 3.4% lower than the $4.69B of fiscal 2025.

What is the growth rate of Roivant Sciences's net assets?

Over the five fiscal years to 2026 net assets grew at a compound 20.3% a year.

What are the highest and lowest net assets figures on record for Roivant Sciences?

Across the 6 fiscal years on record (2021–2026), the highest was $5.97B in fiscal 2024 and the lowest $1.16B in fiscal 2023.

How is Roivant Sciences's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Roivant Sciences it is on record here for 6 fiscal years, 2021 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Roivant Sciences (ROIV) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/ROIV/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.